A cost-benefit analysis of immunization for pneumococcal pneumonia

Area of Science:

• Public Health
• Health Economics
• Vaccinology

Background:

• Pneumococcal pneumonia poses a significant health burden.
• Cost-effectiveness of preventative measures like vaccination is crucial for healthcare planning.

Purpose of the Study:

• To assess the economic viability of pneumococcal vaccination programs.
• To determine if immunization offers a favorable benefit-to-cost ratio for a defined population.

Main Methods:

• Utilized retrospective data on costs associated with pneumococcal pneumonia.
• Incorporated forecasts on vaccine effectiveness and disease incidence.
• Evaluated provider- and patient-centered costs and benefits.

Main Results:

• A pneumococcal vaccination program was found to be cost-beneficial.
• The economic justification was established when considering all associated costs and benefits.

Conclusions:

• Immunization against pneumococcal pneumonia is economically justified for high-risk groups.
• Targeted vaccination strategies for older adults and individuals with chronic illnesses are recommended based on cost-benefit analysis.